Navigation Links
ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
Date:5/19/2010

MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., the Company's President and Chief Executive Officer is a finalist for the Ernst & Young Entrepreneur Of The Year® 2010 Award in Northern California.  According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities.  Dr. Schall was selected as a finalist from over 100 nominations by a panel of independent judges.  Award recipients will be announced at a special gala event on June 12, 2010, at the San Jose Fairmont Hotel.

Dr. Schall is being recognized for his role in founding and leading ChemoCentryx, a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer.  As one of the earliest investigators in the field of chemokine biology, Dr. Schall and his team at ChemoCentryx have successfully established one of the broadest pipelines of chemokine-based therapeutics in the pharmaceutical industry, with five products now in clinical development.

"I am honored to be included in such a prestigious program," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "It has been an extremely rewarding experience to work with this gifted ChemoCentryx team to build the Company and help bring us closer to providing valuable new treatment options for patients who suffer from autoimmune and
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
3. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
4. ChemoCentryxs Traficet-EN(TM) Phase II/III Induction Phase Data in Crohns Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
5. KGI Names Kerry Howell Vice President for Advancement
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. CryoLife Names Philip Theodore as Vice President, General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Global & USA BioSimilar Market Analysis to 2021" ... awaited US Biosimilar market will be initiated in September ... How will the global market react? Will biosimilars explode ... could save the US economy up to $250 billion ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... ... in Personalized Medicine, presented two studies at the International Spine Intervention Society’ ... July 28th, 2015 through to August 1st, 2015. With a focus on evidence-based ...
(Date:8/28/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today ... 30, 2015, corporate highlights, and near-term milestones.  The ... at www.sedar.com ,  www.edgar.com and ... expects to launch its RCS-01 treatment for aging ...
(Date:8/28/2015)... ... ... launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the ... Fonz in a lab coat and Large Marge have been posted on the company’s Facebook ... FireflySci is proud to be the only cuvette manufacturer is the world that has an ...
Breaking Biology Technology:Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2
... of Anesiva,s Needle-Free Technology, SOUTH SAN ... Anesiva, Inc. (Nasdaq: ANSV ) and ... entered into an,agreement granting Particle Therapeutics a ... into its needle-free,intradermal delivery system for glucagon, ...
... 30 Medarex, Inc.,(Nasdaq: MEDX ) announced today ... Partners Healthcare Conference at 11:30 AM Eastern Time on,Wednesday, ... the Four,Seasons Hotel in Boston, Massachusetts. Medarex,s presentation will ... the Webcast page in,the Investor Relations section of the ...
... Aug. 30 Micromet, Inc.,(Nasdaq: MITI ), ... proprietary antibody-based products for cancer, inflammation and,autoimmune diseases, ... Executive Officer of Micromet, will present at the ... on Wednesday,September 5, 2007 at 9:50am Eastern time ...
Cached Biology Technology:Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 2Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 3Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 4Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007 2Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... of the most frustrating problems faced by doctors who treat ... More than 38,000 people in the United States die of ... desperately needed. For almost three decades, scientists and physicians ... mutated in virtually all pancreatic cancers, making it an important ...
... known that large volcanic explosions can affect the weather ... the air. Some suspect that extended "volcanic winters" ... In the summer following Indonesia,s 1815 Tambora ... England, and the 1991 blowout of the Philippines, Mount ...
... Calif.Calcium regulates many critical processes within the body, including ... But too much calcium can be a bad thing. ... diseases, such as severe muscle weakness, a fatal reaction ... intense X-rays from the Stanford Synchrotron Radiation Lightsource (SSRL) ...
Cached Biology News:UNC team discovers promising target for new pancreatic cancer treatments 2Volcanic eruptions affect rainfall over Asian monsoon region 2Volcanic eruptions affect rainfall over Asian monsoon region 3X-rays offer first detailed look at hotspots for calcium-related disease 2
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Biology Products: